# Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia

> **NCT02523976** · PHASE2 · COMPLETED · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 30 (actual)

## Conditions studied

- Acute,Leukemia, Lymphoid

## Interventions

- **DRUG:** Dasatinib
- **DRUG:** prednisone
- **DRUG:** cyclophosphamide
- **DRUG:** daunorubicin
- **DRUG:** vincristine
- **DRUG:** cytarabine
- **DRUG:** mercaptopurine
- **DRUG:** methotrexate
- **DRUG:** dexamethasone
- **DRUG:** mitoxantrone
- **DRUG:** etoposide
- **PROCEDURE:** allogeneic hematopoietic stem cell transplantation
- **PROCEDURE:** autologous hematopoietic stem cell transplantation

## Key facts

- **NCT ID:** NCT02523976
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08-01
- **Primary completion:** 2021-12-31
- **Final completion:** 2021-12-31
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2026-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02523976

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02523976, "Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02523976. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*